109 related articles for article (PubMed ID: 20029947)
1. Prognosis and survivorship in primary myelofibrosis.
Reilly JT
Am J Hematol; 2010 Jan; 85(1):4-5. PubMed ID: 20029947
[No Abstract] [Full Text] [Related]
2. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
3. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
Hidaka T; Shide K; Shimoda H; Kameda T; Toyama K; Katayose K; Kubuki Y; Nagata K; Takenaka K; Akashi K; Okamura T; Niho Y; Mizoguchi H; Omine M; Ozawa K; Harada M; Shimoda K
Eur J Haematol; 2009 Oct; 83(4):328-33. PubMed ID: 19549278
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H; Lioznov M; Fritzsche-Friedland U; Badbaran A; Zabelina T; Bacher U; Stübig T; Ayuk FA; Zander AR; Kröger N
Bone Marrow Transplant; 2012 Jan; 47(1):143-5. PubMed ID: 21358677
[No Abstract] [Full Text] [Related]
5. [Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way].
Merup M; Palmblad J
Lakartidningen; 2009 Dec 2-8; 106(49):3342, 3344-6. PubMed ID: 20104733
[No Abstract] [Full Text] [Related]
6. Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center.
Tefferi A
Eur J Haematol; 2009 Oct; 83(4):290-1. PubMed ID: 19558507
[No Abstract] [Full Text] [Related]
7. Advances in the therapy of chronic idiopathic myelofibrosis.
Arana-Yi C; Quintás-Cardama A; Giles F; Thomas D; Carrasco-Yalan A; Cortes J; Kantarjian H; Verstovsek S
Oncologist; 2006 Sep; 11(8):929-43. PubMed ID: 16951397
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic myelofibrosis: pathogenesis to treatment.
Reilly JT
Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
[TBL] [Abstract][Full Text] [Related]
9. [Myelofibrosis with myeloid metaplasia: diagnosis and treatment].
Dupriez B; Demory JL
Rev Prat; 2005 Oct; 55(15):1680-5. PubMed ID: 16334205
[TBL] [Abstract][Full Text] [Related]
10. Abnormal (marker) chromosomes in two patients with acute myelofibrosis.
Mitus WJ; Coleman N; Kiossoglou KA
Arch Intern Med; 1969 Feb; 123(2):192-7. PubMed ID: 5763618
[No Abstract] [Full Text] [Related]
11. Medical progress in idiopathic myelofibrosis.
Okamura T
Intern Med; 2003 Jun; 42(6):461-2. PubMed ID: 12857040
[No Abstract] [Full Text] [Related]
12. A novel cytogenetic abnormality in primary myelofibrosis.
Bae SY; Kim JS; Lee KN; Lee CK; Kim YK; Yoon SY; Lim CS; Cho YJ; Choi CW; Kim WY
Cancer Genet Cytogenet; 2009 Oct; 194(1):65-6. PubMed ID: 19737657
[No Abstract] [Full Text] [Related]
13. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
14. Stem-cell transplantation for myelofibrosis.
Deeg HJ; Appelbaum FR
N Engl J Med; 2001 Mar; 344(10):775-6. PubMed ID: 11236794
[No Abstract] [Full Text] [Related]
15. [Primary chronic myelofibrosis in the Japanese population].
Okamura T; Shimoda K
Rinsho Ketsueki; 2005 May; 46(5):330-8. PubMed ID: 16444966
[No Abstract] [Full Text] [Related]
16. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method.
Kreft A; Weiss M; Wiese B; Choritz H; Buhr T; Büsche G; Georgii A
Ann Hematol; 2003 Oct; 82(10):605-11. PubMed ID: 14564478
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
Tefferi A
Bone Marrow Transplant; 2010 Mar; 45(3):419-21. PubMed ID: 20216545
[No Abstract] [Full Text] [Related]
18. Myelofibrosis in myeloid malignancies with 3q26 cytogenetic abnormalities.
Sancho JM; Ribera JM; Granada I; Navarro JT; Millá F; Feliu E
Haematologica; 2000 May; 85(5):554-5. PubMed ID: 10800180
[No Abstract] [Full Text] [Related]
19. Chromosome aberrations including der(6)t(2;6)(p15;p21.3) and der(22)t(3;22)(p21;p11) in the evolution of essential thrombocythemia to myelofibrosis with myeloid metaplasia.
Lazarevic V; Andersson C; Wahlin A; Golovleva I
Cancer Genet Cytogenet; 2006 Feb; 165(1):87-9. PubMed ID: 16490605
[No Abstract] [Full Text] [Related]
20. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.
Strasser-Weippl K; Steurer M; Kees M; Augustin F; Tzankov A; Dirnhofer S; Fiegl M; Simonitsch-Klupp I; Gisslinger H; Zojer N; Ludwig H
Cancer; 2006 Dec; 107(12):2801-6. PubMed ID: 17103442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
